Answers are grounded in this paper and cite their sources.
Background: The global incidence of severe acute pancreatitis (SAP) is increasing, yet mortality rates remain persistently high. Novel therapeutic approaches are urgently needed to improve outcomes. The aim of this study is to evaluate the efficacy of high-dose intravenous vitamin C in improving organ support-free days within the first 14 days and other clinical outcomes in patients with SAP. Method: < 0.05. This study will be conduct at eight hospitals in China, including Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital, Shanghai General Hospital, Changhai Hospital, Sichuan Provincial People's Hospital, Chongqing Daping Hospital, The Second People's Hospital of Chengdu, Guanghan People's Hospital and Chongqing Emergency Medical Center. Eligible patients are adults (age ≥ 18 years) diagnosed with severe acute pancreatitis according to 2012 Atlanta classification within 7 days of onset. HDIVC (500 mg/kg, 2 g/h) or placebo (normal saline) will be administered via central vein for 7 days. The primary outcome is organ support-free days within the first 14 days. Secondary outcomes include ICU all-cause mortality, changes in inflammatory biomarkers, and organ failure scores. Discussion: If proven effective, the results of this trial could establish high-dose intravenous vitamin C as a cost-effective adjunctive therapy to improve survival in patients with severe acute pancreatitis and potentially inform future clinical practice guidelines. Clinical trial registration: ClinicalTrials.gov, identifier NCT06897384.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: